Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 24, 2017
What is the competitive landscape for PHARMACIA, and when can generic versions of PHARMACIA drugs launch?
PHARMACIA has one hundred and thirty-seven approved drugs.| Patents: | 9 |
| Tradenames: | 111 |
| Ingredients: | 86 |
| NDAs: | 137 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
linezolid | Injection | 2 mg/mL, 100 mL bag | ZYVOX | 12/29/2009 |
linezolid | Injection | 2 mg/mL, 300 mL bag | ZYVOX | 9/1/2009 |
linezolid | Oral Suspension | 100 mg/5 mL | ZYVOX | 8/3/2009 |
tolterodine tartrate | Extended-release Capsules | 2 mg and 4 mg | DETROL LA | 7/30/2007 |
linezolid | Tablets | 600 mg | ZYVOX | 12/21/2005 |
colestipol hydrochloride | Tablets | 1 g | COLESTID | 8/23/2005 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5,955,346 | Variants of human prolactin and human placeatal lactogen | ► Subscribe | |||||||||||||
| 6,143,523 | Human growth hormone variants | ► Subscribe | |||||||||||||
| 6,004,931 | Method for inhibiting growth hormone action | ► Subscribe | |||||||||||||
| 6,057,292 | Method for inhibiting growth hormone action | ► Subscribe | |||||||||||||
| 5,534,617 | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 | ► Subscribe | |||||||||||||
| 5,780,279 | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display | ► Subscribe | |||||||||||||
| 6,444,813 | Linezolid-crystal form II | ► Subscribe | |||||||||||||
| 6,428,954 | Method for identifying active domains and amino acid residues in polypeptides and hormone variants | ► Subscribe | |||||||||||||
| 6,780,613 | Growth hormone variants | ► Subscribe | |||||||||||||
| 5,750,373 | Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hungary | 0301076 | ► Subscribe | |||||||||||||
| Austria | 354390 | ► Subscribe | |||||||||||||
| Canada | 2400118 | ► Subscribe | |||||||||||||
| European Patent Office | 1568771 | ► Subscribe | |||||||||||||
| Norway | 20002754 | ► Subscribe | |||||||||||||
| Slovakia | 12092002 | ► Subscribe | |||||||||||||
| Australia | 3275501 | ► Subscribe | |||||||||||||
| Slovakia | 15982002 | ► Subscribe | |||||||||||||
| Taiwan | I256310 | ► Subscribe | |||||||||||||
| Japan | H04502454 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 401 | Luxembourg | ► Subscribe | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE | ||||||||||||
| 00221 | Netherlands | ► Subscribe | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 | ||||||||||||
| /2002 | Austria | ► Subscribe | PRODUCT NAME: LINEZOLID; NAT. REGISTRATION NO/DATE: 1-24227 - 1-24230 20011009; FIRST REGISTRATION: GB PL 00032/0259 - PL 00032/0262 20010105 | ||||||||||||
| C/GB01/025 | United Kingdom | ► Subscribe | PRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105 | ||||||||||||
| C0038 | France | ► Subscribe | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 | ||||||||||||
| 2009 | Austria | ► Subscribe | PRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103 | ||||||||||||
| /2004 | Austria | ► Subscribe | PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211 | ||||||||||||
| C/GB96/053 | United Kingdom | ► Subscribe | PRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621 | ||||||||||||
| 60031 | Netherlands | ► Subscribe | PRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621 | ||||||||||||
| C/GB04/032 | United Kingdom | ► Subscribe | PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,760 others who get our Drug Patent Expiration Alerts:
